[1] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012; 55, 2005−23. doi:  10.1002/hep.25762
[2] Miao L, Targher G, Byrne CD, et al. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab, 2024; 35, 697−707. doi:  10.1016/j.tem.2024.02.007
[3] Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 2023; 78, 1966−86. doi:  10.1097/HEP.0000000000000520
[4] Nasr P, Ignatova S, Kechagias S, et al. Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies. Hepatol Commun, 2018; 2, 199−210. doi:  10.1002/hep4.1134
[5] Harrison SA, Bedossa P, Guy CD, et al. A phase 3, Randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med, 2024; 390, 497−509. doi:  10.1056/NEJMoa2309000
[6] Lee H, Lee YH, Kim SU, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol, 2021; 19, 2138-47. e10.
[7] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol, 2024; 81, 492−542.
[8] Balci SB, Atak BM, Duman T, et al. A novel marker for prediabetic conditions: Uric acid-to-HDL cholesterol ratio. Bratisl Med J, 2024; 125, 145−8. doi:  10.4149/bll_2023_130
[9] Aktas G. Exploring the link: hemogram-derived markers in type 2 diabetes mellitus and its complications. World J Diabetes, 2025; 16, 105233. doi:  10.4239/wjd.v16.i7.105233
[10] Kosekli MA, Aktas G. The systemic immune inflammation index is a reliable and novel risk factor for metabolic dysfunction-associated fatty liver disease. Curr Med Res Opin, 2025; 41, 247−51. doi:  10.1080/03007995.2025.2463952
[11] Basaran E, Aktas G. Waist-to-height ratio as a novel marker of metabolic syndrome in patients with type 2 diabetes mellitus. Explor Endocr Metab Dis, 2025; 2, 101421. doi:  10.37349/eemd.2025.101421
[12] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci, 2019; 76, 99−128. doi:  10.1007/s00018-018-2947-0
[13] Galli A, Svegliati-Baroni G, Ceni E, et al. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology, 2005; 41, 1074−84.
[14] Stift J, Semmler G, Wöran K, et al. Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. Dig Liver Dis, 2020; 52, 1473−9. doi:  10.1016/j.dld.2020.08.028
[15] Neuberger J, Patel J, Caldwell H, et al. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut, 2020; 69, 1382−403. doi:  10.1136/gutjnl-2020-321299
[16] Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol, 2023; 79, 277−86. doi:  10.1016/j.jhep.2023.04.002
[17] Barr RG, Wilson SR, Rubens D, et al. Update to the society of radiologists in ultrasound liver elastography consensus statement. Radiology, 2020; 296, 263−74. doi:  10.1148/radiol.2020192437
[18] Hydes T, Brown E, Hamid A, et al. Current and emerging biomarkers and imaging modalities for nonalcoholic fatty liver disease: clinical and research applications. Clin Ther, 2021; 43, 1505−22. doi:  10.1016/j.clinthera.2021.07.012
[19] Aktas G. Exploring the link: hemogram-derived markers in type 2 diabetes mellitus and its complications. World J Diabetes, 2025; 16, 105233.
[20] Balci SB, Atak BM, Duman T, et al. A novel marker for prediabetic conditions: Uric acid-to-HDL cholesterol ratio. Bratisl Med J, 2024; 125, 145-8.
[21] Nascimbeni F, Bedossa P, Fedchuk L, et al. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. J Hepatol, 2020; 72, 828−38. doi:  10.1016/j.jhep.2019.12.008
[22] Tremblay MS, Aubert S, Barnes JD, et al. Sedentary Behavior Research Network (SBRN) - Terminology Consensus Project process and outcome. Int J Behav Nutr Phys Act, 2017; 14, 75. doi:  10.1186/s12966-017-0525-8
[23] San-Cristobal R, Navas-Carretero S, Martínez-González MÁ, et al. Contribution of macronutrients to obesity: implications for precision nutrition. Nat Rev Endocrinol, 2020; 16, 305−20. doi:  10.1038/s41574-020-0346-8
[24] Nascimbeni F, Bedossa P, Fedchuk L, et al. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. J Hepatol, 2020; 72, 828-38.
[25] Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology, 2020; 158, 1611-25. e12.
[26] Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut, 2021; 70, 761−74. doi:  10.1136/gutjnl-2019-319664
[27] Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest, 2004; 114, 147−52. doi:  10.1172/JCI200422422
[28] Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol, 2023; 29, 77−98. doi:  10.3350/cmh.2022.0237
[29] Kim Y, Chang Y, Cho YK, et al. Obesity and weight gain are associated with progression of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2019; 17, 543-50. e2.
[30] Chen TP, Lin WY, Chiang CH, et al. Metabolically healthy obesity and risk of non-alcoholic fatty liver disease severity independent of visceral fat. J Gastroenterol Hepatol, 2021; 36, 2903−10. doi:  10.1111/jgh.15544
[31] Lonardo A, Mantovani A, Lugari S, et al. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol, 2020; 19, 359−66. doi:  10.1016/j.aohep.2020.03.001
[32] Zheng J, Li XR, Zhang Y, et al. Hyperuricemia as an effect modifier of the association between metabolic phenotypes and nonalcoholic fatty liver disease in Chinese population. J Transl Med, 2023; 21, 39. doi:  10.1186/s12967-022-03850-5
[33] Xie D, Zhao HR, Lu JM, et al. High uric acid induces liver fat accumulation via ROS/JNK/AP-1 signaling. Am J Physiol Endocrinol Metab, 2021; 320, E1032−43. doi:  10.1152/ajpendo.00518.2020
[34] Chen WY, Deng Y, Li MQ, et al. Serum uric acid and mortality in metabolic dysfunction-associated steatotic liver disease: subgroup differences. Nutr Metab Cardiovasc Dis, 2024; 34, 2771−8. doi:  10.1016/j.numecd.2024.09.015
[35] Lanaspa MA, Sanchez-Lozada LG, Choi YJ, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress. J Biol Chem, 2012; 287, 40732−44. doi:  10.1074/jbc.M112.399899
[36] Xu ZX, Tang CX, Song X, et al. High uric acid exacerbates nonalcoholic steatohepatitis through NLRP3 inflammasome and gasdermin D-mediated pyroptosis. J Biol Chem, 2025; 301, 110249. doi:  10.1016/j.jbc.2025.110249
[37] Al-Shargi A, El Kholy AA, Adel A, et al. Allopurinol versus febuxostat: a new approach for the management of hepatic steatosis in metabolic dysfunction-associated steatotic liver disease. Biomedicines, 2023; 11, 3074. doi:  10.3390/biomedicines11113074
[38] Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: facts and figures. JHEP Rep, 2019; 1, 468−79. doi:  10.1016/j.jhepr.2019.10.008
[39] Fan J, Wang DX. Serum uric acid and nonalcoholic fatty liver disease. Front Endocrinol, 2024; 15, 1455132. doi:  10.3389/fendo.2024.1455132
[40] Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells, 2020; 9, 1005. doi:  10.3390/cells9041005
[41] Vali Y, Lee J, Boursier J, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol, 2023; 8, 714−25. doi:  10.1016/S2468-1253(23)00017-1
[42] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol, 2024; 81, 492-542.
[43] Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 2022; 71, 1006−19. doi:  10.1136/gutjnl-2021-324243
[44] Steinberg GR, Valvano CM, De Nardo W, et al. Integrative metabolism in MASLD and MASH: pathophysiology and emerging mechanisms. J Hepatol, 2025; 83, 584−95. doi:  10.1016/j.jhep.2025.02.033
[45] Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care, 2017; 40, 419−30. doi:  10.2337/dc16-1787
[46] Younes R, Bugianesi E. NASH in lean individuals. Semin Liver Dis, 2019; 39, 86−95. doi:  10.1055/s-0038-1677517
[47] Mascaró CM, Bouzas C, Montemayor S, et al. Effect of a six-month lifestyle intervention on the physical activity and fitness status of adults with NAFLD and metabolic syndrome. Nutrients, 2022; 14, 1813. doi:  10.3390/nu14091813
[48] Zhang YT, Xie MX, Wen J, et al. Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy. Gut, 2025; 74, 639−51. doi:  10.1136/gutjnl-2024-333154
[49] Caddeo A, Spagnuolo R, Maurotti S. MBOAT7 in liver and extrahepatic diseases. Liver Int, 2023; 43, 2351−64. doi:  10.1111/liv.15706
[50] Zhu YX, Xu XM, Fan ZW, et al. Different minimal alcohol consumption in male and female individuals with metabolic dysfunction-associated fatty liver disease. Liver Int, 2024; 44, 865−75. doi:  10.1111/liv.15849
[51] Li G, Tang LJ, Zhu PW, et al. PNPLA3 rs738409 C>G variant influences the association between visceral fat and significant fibrosis in biopsy-proven nonalcoholic fatty liver disease. J Clin Transl Hepatol, 2022; 10, 439−48. doi:  10.14218/JCTH.2021.00286
[52] Fouad Y, Pan ZY, Nafady S, et al. HOMA-IR, an independent predictor of advanced liver fibrosis in metabolic-dysfunction associated fatty liver disease: a cross-sectional study in Egyptian patients. Sci Rep, 2025; 15, 31098. doi:  10.1038/s41598-025-15425-7
[53] Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 2022; 71, 1006-19.
[54] Lee J, Vali Y, Boursier J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int, 2021; 41, 261−70.